Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altimmune, Inc.

4.28
+0.02000.47%
Pre-market: 4.300.0200+0.47%07:05 EST
Volume:2.98M
Turnover:12.60M
Market Cap:446.59M
PE:-4.05
High:4.31
Open:4.26
Low:4.14
Close:4.26
52wk High:11.16
52wk Low:2.90
Shares:104.34M
Float Shares:104.00M
Volume Ratio:0.73
T/O Rate:2.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0561
EPS(LYR):-1.3388
ROE:-52.61%
ROA:-30.87%
PB:2.41
PE(LYR):-3.20

Loading ...

Altimmune Inc. Publishes Results of Phase 2b Trial of Pemvidutide in MASH

Reuters
·
Yesterday

Altimmune announces publication of IMPACT Phase 2b trial data

TIPRANKS
·
Yesterday

Altimmune Announces Publication of Impact Phase 2B Trial Data in the Lancet and Concurrent Late-Breaking Oral Presentation at Aasld the Liver Meeting® 2025

THOMSON REUTERS
·
Yesterday

Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), Dogwood Therapeutics (DWTX)

TIPRANKS
·
Nov 08

Altimmune Is Maintained at Market Outperform by Citizens

Dow Jones
·
Nov 07

Altimmune announce results from analysis of biopsies from IMPACT Phase 2b trial

TIPRANKS
·
Nov 07

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

GlobeNewswire
·
Nov 07

BRIEF-Altimmune Files For Offering Of Common Stock Of Up To $200 Million - Filing

Reuters
·
Nov 07

Altimmune Inc Files for Mixed Shelf of up to $400 Mln - SEC Filing

THOMSON REUTERS
·
Nov 07

Altimmune: Files for Offering of Common Stock of up to $200 Mln - Filing

THOMSON REUTERS
·
Nov 07

BRIEF-Altimmune Amends Loan And Security Agreement With Hercules Capital - SEC Filing

Reuters
·
Nov 06

Altimmune Inc - Amends Loan and Security Agreement With Hercules Capital - SEC Filing

THOMSON REUTERS
·
Nov 06

Altimmune Inc - Term Loan Increased From $100 Mln to $125 Mln - SEC Filing

THOMSON REUTERS
·
Nov 06

Altimmune Q3 revenue beats expectations

Reuters
·
Nov 06

Altimmune Q3 Basic EPS USD -0.21

THOMSON REUTERS
·
Nov 06

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

THOMSON REUTERS
·
Nov 06

Immunocore reports third quarter financial results and provides a business update

GlobeNewswire
·
Nov 06

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 06

Altimmune Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
Nov 04

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

GlobeNewswire
·
Nov 03